Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Brokers have set a 1-year consensus price objective of $8.00 for the company, according to Zacks. Zacks has also given Sonoma Pharmaceuticals an industry rank of 80 out of 265 based on the ratings given to related companies.
Separately, Maxim Group set a $8.00 price objective on shares of Sonoma Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, November 11th.
Shares of Sonoma Pharmaceuticals (NASDAQ:SNOA) opened at 5.99 on Friday. The company’s market cap is $25.23 million. Sonoma Pharmaceuticals has a 1-year low of $3.57 and a 1-year high of $6.65. The stock’s 50 day moving average is $5.16 and its 200 day moving average is $4.50.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.
Get a free copy of the Zacks research report on Sonoma Pharmaceuticals (SNOA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com